Trial | NCT02352649  Report issue

Title

Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury
1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    45
The purpose of this study is to determine safety and efficacy of pl-vegf165 ("Neovasculgen") for regeneration of peripheral nerve. Pl-vegf165 ("Neovasculgen") is the permitted in Russian Federation angiogenic medication that induce growth of new vessels and included in a complex therapy for patients with peripheral arterial diseases in Russia. It has also been shown to enhance nerve regeneration and muscle reinnervation in animals but these properties have not previously been studied in patients. Moreover, currently there is no method in clinical use to speed the rate of recovery after nerve injury. The objective of this study is to explore the ability of pl-vegf165 to benefit the treatment of patients with peripheral nerve injury. The investigators hypothesize that treatment with intraneural injections with pl-vegf165 after peripheral nerve reconstruction will accelerate nerve regeneration, reduce the period of denervation and improve muscle reinnervation and recovery in patients with peripheral nerve injury.
All patients enrolled into the study will receive standard surgery procedures indicated in accordance with medical care standards for the certain disease. Patients after nerve injury classified as neurotmesis will receive surgical repair of injured nerves what will be added by intraneural injections of pl-vegf165. Safety and efficacy of gene therapy will be assessed by physical examination, comprehensive laboratory tests over next 18 month after surgical nerve reconstruction.
Study Started
Apr 30
2015
Primary Completion
Mar 31
2016
Anticipated
Study Completion
Sep 30
2017
Anticipated
Last Update
Feb 02
2015
Estimate

Drug Neovasculgen

Neovasculgen 1 Experimental

Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.

Neovasculgen 2 Experimental

Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.

water for injections Placebo Comparator

Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.

Criteria 

Inclusion Criteria:

Patients with confirmed transection injury between shoulder and wrist
Isolated injury of ulnar or median nerve (not mixed injury of several nerves)
Nerve injuries which are amenable to direct end-to-end repair
Length of the gap between of stumps of transected nerve no longer than 3,5 centimeters
Early delayed (secondary) repair performed between 2 to 6 weeks after nerve injury

Exclusion Criteria:

Length of the gap between of stumps of transected nerve more than 3,5 centimeters
Simultaneous injury of several peripheral nerves
Localization of nerve injury beyond of forearm
Presence of neurological deficit preceding to nerve injury
Systemic disease of connective tissue
Myopathy
Large surgical procedures planned for next one and a half year
Presence of oncological diseases
Pregnancy and breastfeeding
Alcohol and drug addiction
Patient ability to adhere strictly to the rules of the current clinical trial protocol
No Results Posted